Sevirumab

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Sevirumab
Monoclonal antibody
Type ?
Source Human
Target CMV
Clinical data
ATC code
  • none
Identifiers
ChemSpider
  • none
  (verify)

Sevirumab (MSL-109) is a human monoclonal antibody for the treatment of infections with cytomegalovirus in patients with AIDS.[1][2]

References[edit]

  1. ^ Borucki, MJ; Spritzler, J; Asmuth, DM; Gnann, J; Hirsch, MS; Nokta, M; Aweeka, F; Nadler, PI; et al. (2004). "A phase II, double-masked, randomized, placebo-controlled evaluation of a human monoclonal anti-Cytomegalovirus antibody (MSL-109) in combination with standard therapy versus standard therapy alone in the treatment of AIDS patients with Cytomegalovirus retinitis". Antiviral Research. 64 (2): 103–11. PMID 15498605. doi:10.1016/j.antiviral.2004.06.012. 
  2. ^ ClinicalTrials.gov